Objective: We sought to determine outcomes of aortic valve replacement (AVR) versus root replacement after transcatheter AVR (TAVR) explantation because they remain unknown. Methods: From November 2009 to September 2020, data from the EXPLANTTAVR International Registry of patients who underwent TAVR explant were retrospectively reviewed, divided by AVR versus root replacement. After excluding explants performed during the same admission as the initial TAVR and concomitant procedures involving the other valves, 168 AVR cases were compared with 28 root replacements, and outcomes were reported at 30 days and 1 year. KM Curve for Overall Survival Overall 100 Cumulative Survival (%) 80 60 40 20 0 83.0% 0 At Risk 187 A 6 12 Follow-up months 100 77.2% 80 Stratified by Roor Replacement at Explant Cumulative Survival (%) 60 90.8% 81.6% 40 20 0 24 18 6 0 70.6% 78.6% 24 18 Log Rank P = .54 HR 0.73 (95% CI 0.26 – 2.05) 12 Follow-up months At Risk 28 43 50 66 101 Root Replacement AV 9 11 15 8 R 86 55 41 35 159 B ADULT Summary of the EXPLANT-TAVR International Registry. CENTRAL MESSAGE Results: Among 196 patients (mean age, 73.5 9.9 years) who had primary aortic valve intervention at TAVR explant, the median time from TAVR to surgical explant was 11.2 months (interquartile range, 4.4-32.9 months). Indications for explant were similar between the 2 groups. Compared with AVR, patients requiring root replacement had fewer comorbidities but more unfavorable anatomy for redo TAVR (52.6% vs 26.4%; P ¼ .032), fewer urgent/emergency cases (32.1% vs 58.3%; P ¼ .013), longer median interval from index TAVR to TAVR explant (17.6 vs 9.9 months; P ¼ .047), and more concomitant ascending aortic replacement (58.8% vs 14.0%; P<.001). Median follow-up was 6.9 months (interquartile range, 1.4-21.6 months) after TAVR explant and 97.4% complete. Overall survival at followup was 81.2% with no differences between groups (log rank P ¼ .54). In-hospital, 30-day, and 1-year mortality rates and stroke rates were not different between the 2 groups. Conclusions: In the EXPLANT-TAVR Registry, AVR and root replacement groups had different clinical characteristics, but no differences in short-term mortality and morbidities. Further investigations are necessary to identify patients at risk of root replacement in TAVR explant.
Vitanova, K., Zaid, S., Tang, G., Kaneko, T., Bapat, V.n., Modine, T., et al. (2023). Aortic valve versus root surgery after failed transcatheter aortic valve replacement. THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 166(5), 1418-1430 [10.1016/j.jtcvs.2021.12.060].
Aortic valve versus root surgery after failed transcatheter aortic valve replacement
Augusto D'OnofrioMembro del Collaboration Group
;
2023-01-01
Abstract
Objective: We sought to determine outcomes of aortic valve replacement (AVR) versus root replacement after transcatheter AVR (TAVR) explantation because they remain unknown. Methods: From November 2009 to September 2020, data from the EXPLANTTAVR International Registry of patients who underwent TAVR explant were retrospectively reviewed, divided by AVR versus root replacement. After excluding explants performed during the same admission as the initial TAVR and concomitant procedures involving the other valves, 168 AVR cases were compared with 28 root replacements, and outcomes were reported at 30 days and 1 year. KM Curve for Overall Survival Overall 100 Cumulative Survival (%) 80 60 40 20 0 83.0% 0 At Risk 187 A 6 12 Follow-up months 100 77.2% 80 Stratified by Roor Replacement at Explant Cumulative Survival (%) 60 90.8% 81.6% 40 20 0 24 18 6 0 70.6% 78.6% 24 18 Log Rank P = .54 HR 0.73 (95% CI 0.26 – 2.05) 12 Follow-up months At Risk 28 43 50 66 101 Root Replacement AV 9 11 15 8 R 86 55 41 35 159 B ADULT Summary of the EXPLANT-TAVR International Registry. CENTRAL MESSAGE Results: Among 196 patients (mean age, 73.5 9.9 years) who had primary aortic valve intervention at TAVR explant, the median time from TAVR to surgical explant was 11.2 months (interquartile range, 4.4-32.9 months). Indications for explant were similar between the 2 groups. Compared with AVR, patients requiring root replacement had fewer comorbidities but more unfavorable anatomy for redo TAVR (52.6% vs 26.4%; P ¼ .032), fewer urgent/emergency cases (32.1% vs 58.3%; P ¼ .013), longer median interval from index TAVR to TAVR explant (17.6 vs 9.9 months; P ¼ .047), and more concomitant ascending aortic replacement (58.8% vs 14.0%; P<.001). Median follow-up was 6.9 months (interquartile range, 1.4-21.6 months) after TAVR explant and 97.4% complete. Overall survival at followup was 81.2% with no differences between groups (log rank P ¼ .54). In-hospital, 30-day, and 1-year mortality rates and stroke rates were not different between the 2 groups. Conclusions: In the EXPLANT-TAVR Registry, AVR and root replacement groups had different clinical characteristics, but no differences in short-term mortality and morbidities. Further investigations are necessary to identify patients at risk of root replacement in TAVR explant.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0022522322003488-main (4).pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
1.63 MB
Formato
Adobe PDF
|
1.63 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.